NAGIOS: RODERIC FUNCIONANDO

Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19

Repositori DSpace/Manakin

Valencià Castellano

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19

Mostra el registre complet de l'element

Visualització (809.4Kb)

Piñana, José Luis; García Sanz, R.; Martino, Rodrigo; García Roa, María; Martín Martín, Gabriel Andrés; Risco Gálvez, Irene; Martino, Rodrigo; Tormo Díaz, Mar; Martínez Barranco, Pilar; Martínez Barranco, Pilar; Marcos Corrales, Sara; Calabuig, Marisa; Conesa, Venancio; Teruel, Anabel; Ruiz Pérez, Sara; Solano Vercet, Carlos; Navarro Ortega, David; Cedillo, Ángel; Sureda, Anna

Aquest document és un/a article, creat/da en: 2022

Patients with hematological malignancies have been excluded from the new zoonotic coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) vaccine trials despite being at higher risk for SARS-CoV-2 disease (COVID-19)-related mortality. However, most health authorities worldwide have designated these patients as a priority for COVID-19 vaccination, even in the absence of efficacy data in these highly immunosuppressed patients. In addition, on 12 August 2021, the US Food and Drug Administration amended the emergency use authorizations for the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow for the use of an additional dose in immunocompromised individuals, such as solid organ transplant recipients or equivalently immunosuppressed patients.

Veure al catàleg Trobes